103 related articles for article (PubMed ID: 26113475)
1. Urocortin 2 protects heart and kidney structure and function in an ovine model of acute decompensated heart failure: Comparison with dobutamine.
Rademaker MT; Ellmers LJ; Charles CJ; Mark Richards A
Int J Cardiol; 2015 Oct; 197():56-65. PubMed ID: 26113475
[TBL] [Abstract][Full Text] [Related]
2. Urocortin 2 inhibits furosemide-induced activation of renin and enhances renal function and diuretic responsiveness in experimental heart failure.
Rademaker MT; Charles CJ; Nicholls MG; Richards AM
Circ Heart Fail; 2009 Nov; 2(6):532-40. PubMed ID: 19919977
[TBL] [Abstract][Full Text] [Related]
3. Urocortin 2 sustains haemodynamic and renal function during introduction of beta-blockade in experimental heart failure.
Rademaker MT; Charles CJ; Nicholls G; Richards M
J Hypertens; 2011 Sep; 29(9):1787-95. PubMed ID: 21720262
[TBL] [Abstract][Full Text] [Related]
4. Urocortin 2 combined with angiotensin-converting enzyme inhibition in experimental heart failure.
Rademaker MT; Charles CJ; Nicholls MG; Richards AM
Clin Sci (Lond); 2008 May; 114(10):635-42. PubMed ID: 18052934
[TBL] [Abstract][Full Text] [Related]
5. Integrated hemodynamic, hormonal, and renal actions of urocortin 2 in normal and paced sheep: beneficial effects in heart failure.
Rademaker MT; Cameron VA; Charles CJ; Richards AM
Circulation; 2005 Dec; 112(23):3624-32. PubMed ID: 16330704
[TBL] [Abstract][Full Text] [Related]
6. Interactions of enhanced urocortin 2 and mineralocorticoid receptor antagonism in experimental heart failure.
Rademaker MT; Charles CJ; Nicholls MG; Richards AM
Circ Heart Fail; 2013 Jul; 6(4):825-32. PubMed ID: 23753530
[TBL] [Abstract][Full Text] [Related]
7. Prolonged urocortin 2 administration in experimental heart failure: sustained hemodynamic, endocrine, and renal effects.
Rademaker MT; Charles CJ; Ellmers LJ; Lewis LK; Nicholls MG; Richards AM
Hypertension; 2011 Jun; 57(6):1136-44. PubMed ID: 21536988
[TBL] [Abstract][Full Text] [Related]
8. Urocortin-2 infusion in acute decompensated heart failure: findings from the UNICORN study (urocortin-2 in the treatment of acute heart failure as an adjunct over conventional therapy).
Chan WY; Frampton CM; Crozier IG; Troughton RW; Richards AM
JACC Heart Fail; 2013 Oct; 1(5):433-41. PubMed ID: 24621976
[TBL] [Abstract][Full Text] [Related]
9. Beneficial hemodynamic, endocrine, and renal effects of urocortin in experimental heart failure: comparison with normal sheep.
Rademaker MT; Charles CJ; Espiner EA; Fisher S; Frampton CM; Kirkpatrick CM; Lainchbury JG; Nicholls MG; Richards AM; Vale WW
J Am Coll Cardiol; 2002 Oct; 40(8):1495-505. PubMed ID: 12392842
[TBL] [Abstract][Full Text] [Related]
10. Acute effects of urocortin 2 on cardiac function and propensity for arrhythmias in an animal model of hypertension-induced left ventricular hypertrophy and heart failure.
Meili-Butz S; Bühler K; John D; Buser P; Vale WW; Peterson KL; Brink M; Dieterle T
Eur J Heart Fail; 2010 Aug; 12(8):797-804. PubMed ID: 20388649
[TBL] [Abstract][Full Text] [Related]
11. Chronic urocortin 2 administration improves cardiac function and ameliorates cardiac remodeling after experimental myocardial infarction.
Ellmers LJ; Scott NJ; Cameron VA; Richards AM; Rademaker MT
J Cardiovasc Pharmacol; 2015 Mar; 65(3):269-75. PubMed ID: 25658462
[TBL] [Abstract][Full Text] [Related]
12. Combined angiotensin-converting enzyme inhibition and adrenomedullin in an ovine model of heart failure.
Rademaker MT; Charles CJ; Cooper GJ; Coy DH; Espiner EA; Lewis LK; Nicholls MG; Richards AM
Clin Sci (Lond); 2002 Jun; 102(6):653-60. PubMed ID: 12049620
[TBL] [Abstract][Full Text] [Related]
13. Identifying Candidate Protein Markers of Acute Kidney Injury in Acute Decompensated Heart Failure.
Templeton EM; Lassé M; Kleffmann T; Ellmers LJ; Palmer SC; Davidson T; Scott NJA; Pickering JW; Charles CJ; Endre ZH; Cameron VA; Richards AM; Rademaker MT; Pilbrow AP
Int J Mol Sci; 2022 Jan; 23(2):. PubMed ID: 35055195
[TBL] [Abstract][Full Text] [Related]
14. Urocortin 2 induces potent long-lasting inhibition of cardiac sympathetic drive despite baroreflex activation in conscious sheep.
Charles CJ; Jardine DL; Rademaker MT; Richards AM
J Endocrinol; 2010 Feb; 204(2):181-9. PubMed ID: 19914944
[TBL] [Abstract][Full Text] [Related]
15. Urocortin 2 infusion in human heart failure.
Davis ME; Pemberton CJ; Yandle TG; Fisher SF; Lainchbury JG; Frampton CM; Rademaker MT; Richards M
Eur Heart J; 2007 Nov; 28(21):2589-97. PubMed ID: 17720993
[TBL] [Abstract][Full Text] [Related]
16. Intravenous AAV8 Encoding Urocortin-2 Increases Function of the Failing Heart in Mice.
Lai NC; Gao MH; Giamouridis D; Suarez J; Miyanohara A; Parikh J; Hightower S; Guo T; Dillmann W; Kim YC; Diaz-Juarez J; Hammond HK
Hum Gene Ther; 2015 Jun; 26(6):347-56. PubMed ID: 25760560
[TBL] [Abstract][Full Text] [Related]
17. Lowered B-type natriuretic peptide in response to levosimendan or dobutamine treatment is associated with improved survival in patients with severe acutely decompensated heart failure.
Cohen-Solal A; Logeart D; Huang B; Cai D; Nieminen MS; Mebazaa A
J Am Coll Cardiol; 2009 Jun; 53(25):2343-8. PubMed ID: 19539144
[TBL] [Abstract][Full Text] [Related]
18. Effects of levosimendan versus dobutamine on inflammatory and apoptotic pathways in acutely decompensated chronic heart failure.
Adamopoulos S; Parissis JT; Iliodromitis EK; Paraskevaidis I; Tsiapras D; Farmakis D; Karatzas D; Gheorghiade M; Filippatos GS; Kremastinos DT
Am J Cardiol; 2006 Jul; 98(1):102-6. PubMed ID: 16784930
[TBL] [Abstract][Full Text] [Related]
19. [The dobutamine-dopamine combination versus amrinone in congestive heart failure with a marked edematogenic sign complicated by functional kidney failure. A comparison between 2 different models of inotropic stimulation and diuresis potentiation].
De Vecchis R; Pucciarelli G; Nocerino L; Cocozza M; Setaro A; Torre G; Imperatore F
Minerva Cardioangiol; 1998 May; 46(5):163-74. PubMed ID: 9842199
[TBL] [Abstract][Full Text] [Related]
20. Acute Decompensated Heart Failure and the Kidney: Physiological, Histological and Transcriptomic Responses to Development and Recovery.
Rademaker MT; Pilbrow AP; Ellmers LJ; Palmer SC; Davidson T; Mbikou P; Scott NJA; Permina E; Charles CJ; Endre ZH; Richards AM
J Am Heart Assoc; 2021 Sep; 10(18):e021312. PubMed ID: 34533033
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
